提高CAR-T细胞疗法抗癌活性及安全性的研究进展  

Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy

作　　者：夏涌[1] 黄健[2] 钱其军[1] 

机构地区：[1]第二军医大学附属东方肝胆外科医院生物治疗科,上海200438 [2]第二军医大学附属东方肝胆外科医院肝外三科,上海200438

出　　处：《药学实践杂志》2016年第4期372-376,共5页Journal of Pharmaceutical Practice

摘　　要：经过25年的研究,以嵌合抗原受体(CAR)为基础的细胞治疗目前在治疗恶性肿瘤方面展现了巨大潜力。近几年有大量的相关试验和临床数据被报道,本综述通过对这些数据的对比和分析,讨论如何增强CAR-T细胞疗法对不可切除的恶性肿瘤的治疗效果,也对CAR-T细胞技术在恶性肿瘤临床治疗领域存在的安全问题及解决策略进行概述。The great potential of cell therapy based on chimeric antigen receptor （CAR） has been demonstrated in the treatment of malignant tumors through 25 years of research. A large number of experimental and clinical data have been repor- ted in recent years. This review compares and analyzes these data to discuss how to enhance the efficacy of CAR-T cell therapy in the treatment of unresectable malignant tumors and to summarize the safety issues and solution strategies of CAR-T cell technology in the treatment of malignant tumors.

关 键 词：嵌合抗原受体 过继细胞免疫治疗 肿瘤 

分 类 号：R73[医药卫生—肿瘤]